Anti-PD1 therapy was found to increase the overall T cell population as a percentage of the total immune cell count within tumor tissues, with a pronounced increase in the Tpst2 knock-down + anti-PD1 group (Fig. S12a). This evidence concerns the gene TPST2 and neoplasm.